These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 16224615)

  • 1. Glutamate modulators as novel interventions for mood disorders.
    Mathew SJ; Keegan K; Smith L
    Braz J Psychiatry; 2005 Sep; 27(3):243-8. PubMed ID: 16224615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole.
    Owen RT
    Drugs Today (Barc); 2012 Jul; 48(7):469-78. PubMed ID: 22844658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabotropic glutamate receptors in the control of mood disorders.
    Witkin JM; Marek GJ; Johnson BG; Schoepp DD
    CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):87-100. PubMed ID: 17430147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.
    Machado-Vieira R; Manji HK; Zarate CA
    Neuroscientist; 2009 Oct; 15(5):525-39. PubMed ID: 19471044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects.
    Maeng S; Zarate CA
    Curr Psychiatry Rep; 2007 Dec; 9(6):467-74. PubMed ID: 18221626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.
    Abdallah CG; Sanacora G; Duman RS; Krystal JH
    Annu Rev Med; 2015; 66():509-23. PubMed ID: 25341010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.
    Miller OH; Moran JT; Hall BJ
    Neuropharmacology; 2016 Jan; 100():17-26. PubMed ID: 26211972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression.
    Manji HK; Quiroz JA; Sporn J; Payne JL; Denicoff K; A Gray N; Zarate CA; Charney DS
    Biol Psychiatry; 2003 Apr; 53(8):707-42. PubMed ID: 12706957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid-onset antidepressant efficacy of glutamatergic system modulators: the neural plasticity hypothesis of depression.
    Wang J; Jing L; Toledo-Salas JC; Xu L
    Neurosci Bull; 2015 Feb; 31(1):75-86. PubMed ID: 25488282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The potential of group II metabotropic glutamate receptor antagonists as a novel antidepressant].
    Chaki S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Aug; 32(4):219-26. PubMed ID: 23012890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A role for AMPA receptors in mood disorders.
    Alt A; Nisenbaum ES; Bleakman D; Witkin JM
    Biochem Pharmacol; 2006 Apr; 71(9):1273-88. PubMed ID: 16442080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketamine for treatment-resistant unipolar depression: current evidence.
    Mathew SJ; Shah A; Lapidus K; Clark C; Jarun N; Ostermeyer B; Murrough JW
    CNS Drugs; 2012 Mar; 26(3):189-204. PubMed ID: 22303887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel drugs and therapeutic targets for severe mood disorders.
    Mathew SJ; Manji HK; Charney DS
    Neuropsychopharmacology; 2008 Aug; 33(9):2080-92. PubMed ID: 18172433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Riluzole in the treatment of mood and anxiety disorders.
    Pittenger C; Coric V; Banasr M; Bloch M; Krystal JH; Sanacora G
    CNS Drugs; 2008; 22(9):761-86. PubMed ID: 18698875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of the glutamatergic system in pathophysiology and pharmacotherapy for depression: preclinical and clinical data].
    Paslakis G; Gass P; Deuschle M
    Fortschr Neurol Psychiatr; 2011 Apr; 79(4):204-12. PubMed ID: 21117011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ketamine's antidepressant effect: focus on ketamine mechanisms of action].
    De Maricourt P; Jay T; Goncalvès P; Lôo H; Gaillard R
    Encephale; 2014 Feb; 40(1):48-55. PubMed ID: 24434007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NMDA antagonist treatment of depression.
    Williams NR; Schatzberg AF
    Curr Opin Neurobiol; 2016 Feb; 36():112-7. PubMed ID: 26687375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AMPA receptors in the therapeutic management of depression.
    Bleakman D; Alt A; Witkin JM
    CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):117-26. PubMed ID: 17430149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in depression: central mediators of pathophysiology and antidepressant activity?
    Freudenberg F; Celikel T; Reif A
    Neurosci Biobehav Rev; 2015 May; 52():193-206. PubMed ID: 25783220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutamatergic modulators: the future of treating mood disorders?
    Zarate C; Machado-Vieira R; Henter I; Ibrahim L; Diazgranados N; Salvadore G
    Harv Rev Psychiatry; 2010; 18(5):293-303. PubMed ID: 20825266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.